Overview

Disulfiram and Cisplatin in Refractory TGCTs.

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs).

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute, Slovakia

Treatments:

Cisplatin
Disulfiram